-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を3ドル引き下げ、240ドルとします。これは、2026年EPS予想(倍率は変更なし)の13倍に相当し、EXPEの過去5年間の平均予想倍率21倍を大きく下回ります。2026年EPS予想を18.55ドルから18.51ドルに、2027年EPS予想を20.42ドルから20.38ドルにそれぞれ引き下げます。これは、受注残高の伸びがやや鈍化するとの見通しを反映したものです。マクロ経済リスクの高まりと、同社の米国事業への集中度を考慮すると、株価は過大評価されていると判断し、EXPEの投資判断を「ホールド」から「セル」に引き下げます。原油価格の高騰は米国の消費者の裁量支出を圧迫しており、EXPEは事業の約60%が米国事業であるため、同業他社と比較してその影響をより大きく受けると考えられます。最近の予約好調を受けて、コンセンサス売上高予測は6%上方修正されたものの、近年のマクロ経済の変動を反映するには時間がかかっており、下振れリスクの可能性を示唆している。さらに、AIを活用した検索・予約ツールは、EXPEの従来型オンライン旅行代理店モデルにとって、長期的な仲介排除の脅威となる。
Related Articles
Hongqiao Aluminum's Profit Jumps 38%, Revenue Up 3%
Shandong Hongqiao Aluminum Industry (SHE:002379) reported a 38% jump in attributable net profit in the first quarter of 2026 to 6.76 billion yuan from 4.91 billion yuan, according to a filing on the Shenzhen Stock Exchange over the weekend.Diluted earnings per share rose to 0.5186 yuan from 0.3770 yuan.The aluminum company's revenue edged up 3.21% to 40.9 billion yuan from 39.7 billion yuan.
Cofoe Medical Technology Seeks Up to HK$1.06 Billion in Hong Kong IPO
Cofoe Medical Technology (HKG:1187, SHE:301087) launched its Hong Kong initial public offering on Monday, seeking to raise up to about HK$1.06 billion from the deal.The China-based home care medical device provider is offering 27 million H-shares at a maximum offer price of HK$39.33 per share, according to a Hong Kong bourse filing.The offering comprises 2.7 million shares for Hong Kong investors and 24.3 million shares for international investors, subject to reallocation.The offer price is expected to be determined by May 4, with allocation results due by May 5, ahead of the company's planned trading debut on May 6.Net proceeds will be used mainly to support global expansion and strengthen overseas sales channels, as well as advance product research and development.The funds will also be used to expand domestic distribution networks, enhance branding and marketing efforts, and for working capital and general corporate purposes.Huatai Financial Holdings (Hong Kong) and BNP Paribas Securities (Asia) are acting as joint sponsors.Huatai Financial Holdings (Hong Kong) and BNP Paribas Securities (Asia) are serving as overall coordinators and are also acting as joint bookrunners and joint lead managers, alongside Futu Securities International (Hong Kong).
CMOC Group's Q1 Profit Nearly Doubles as Revenue Jumps 44%
CMOC Group (SHA:603993, HKG:3993) reported a 97% jump in attributable net profit in the first quarter of 2026 to 7.76 billion yuan from 3.95 billion yuan a year ago, according to filings on the Shanghai and Hong Kong bourses over the weekend.Diluted earnings per share doubled to 0.36 yuan from 0.18 yuan.The copper and cobalt producer's revenue edged up 44% to 66.4 billion yuan from 46 billion yuan.